TapewireFind a company

person · Reporting owner

Stokes Frank

Disclosed activity across 2 companies

Tapewire entity
22194
SEC CIK
0001782815

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CASTLE BIOSCIENCES INCCSTL · Entity 359Chief Financial OfficerAugust 14, 2026August 18, 2026
EXAGEN INC.XGN · Entity 935DirectorJune 09, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CASTLE BIOSCIENCES INC

Report date August 14, 2026 · Filed August 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect35,177 Reported balance After 2026-08-14 transaction · row 1
1 source row

Row 1 · 2026-08-14 · Sale · Disposed 24,908 · Balance 35,177

F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

EXAGEN INC.

Report date June 09, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08Direct112,500 Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 112,500

F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 14, 2026 Filed Aug 18, 2026 20:10 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 24,908 $29.77 $741,511.16
Disclosure

SEC source: 0001628280-26-057644 · wk-form4_1787083838.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,177

F1 · price: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 09, 2026 Filed Jun 22, 2026 17:00 UTC EXAGEN INC. XGN · Entity 935 GrantStock Option(right to buy) · Derivative 37,500 $0.00 Strike: $4.31 $0.00
Disclosure

SEC source: 0001782815-26-000007 · wk-form4_1782147613.xml · derivative · entry 1

Stokes Frank · CIK 0001782815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 37,500 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 6,001 $27.98 $167,907.98
Disclosure

SEC source: 0001628280-26-016019 · wk-form4_1773087231.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,085

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.51 to $28.41, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 3,800 $0.00 Strike: $3.38 $0.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 10

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,912

Underlying: Common Stock · 3,800 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to the option are fully vested.

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 11,960 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 9

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,878

Underlying: Common Stock · 11,960 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F9 · derivative.exercise_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026.

F9 · derivative.expiration_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026.

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 12,186 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 8

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,372

Underlying: Common Stock · 12,186 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F8 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025.

F8 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025.

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 3,800 $3.38 $12,844.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,086

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 10,732 $28.17 $302,320.44
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,286

Read SEC document
March 04, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 24,146 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantRestricted Stock Units · Derivative 48,367 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 7

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,367

Underlying: Common Stock · 48,367 shares

Expires not disclosed

F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 03, 2027.

F7 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 03, 2027.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 3,611 $27.57 $99,555.27
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,872

F5 · shares: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,700 $27.81 $47,277.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,483

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $27.72 to $27.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 22:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,300 $27.32 $144,796.00
Disclosure

SEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,183

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $26.70 to $27.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 1,033 shares acquired on February 27, 2026, under the Issuer's employee stock purchase plan.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:30 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantPerformance-Based Stock Unit · Derivative 8,124 $0.00 $0.00
Disclosure

SEC source: 0001782815-26-000002 · form4-01142026_040101.xml · derivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,124

Underlying: Common Stock · 8,124 shares

Expires not disclosed

F2 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones.

F2 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones.

F2 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:30 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantCommon Stock 8,124 $0.00 $0.00
Disclosure

SEC source: 0001782815-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,450

F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on March 4, 2024 ("2024 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on January 12, 2026.

Read SEC document
December 11, 2025 Filed Dec 15, 2025 21:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 4,496 $37.45 $168,375.20
Disclosure

SEC source: 0001628280-25-057013 · wk-form4_1765832936.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,326

Read SEC document
December 10, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 6,170 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · derivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,170 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022.

F3 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022.

Read SEC document
December 10, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 2,758 $38.02 $104,859.16
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,822

Read SEC document
December 10, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 6,170 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 14,616 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · derivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,617

Underlying: Common Stock · 14,616 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023.

F2 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 6,534 $38.25 $249,925.50
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,410

Read SEC document
December 09, 2025 Filed Dec 11, 2025 23:46 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 14,616 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
November 11, 2025 Filed Nov 13, 2025 21:08 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,388 $35.08 $189,011.04
Disclosure

SEC source: 0001628280-25-052021 · wk-form4_1763068128.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,328

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on August 12, 2025

F2 · price: This transaction was executed in multiple trades at prices ranging from $34.44 to $35.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 08, 2025 Filed Aug 12, 2025 20:31 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionPerformance-Based Stock Unit · Derivative 9,744 $0.00 $0.00
Disclosure

SEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · derivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,744 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024.

F1 · derivative.exercise_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024.

F1 · derivative.expiration_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024.

Read SEC document
August 08, 2025 Filed Aug 12, 2025 20:31 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 4,356 $19.36 $84,332.16
Disclosure

SEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,716

Read SEC document
August 08, 2025 Filed Aug 12, 2025 20:31 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 9,744 $0.00 $0.00
Disclosure

SEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,072

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 22:49 UTC EXAGEN INC. XGN · Entity 935 GrantStock Option(right to buy) · Derivative 9,000 $0.00 Strike: $7.36 $0.00
Disclosure

SEC source: 0001274737-25-000048 · wk-form4_1749768534.xml · derivative · entry 1

Stokes Frank · CIK 0001782815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 12,186 $0.00 $0.00
Disclosure

SEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · derivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,558

Underlying: Common Stock · 12,186 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025.

F4 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantRestricted Stock Units · Derivative 47,838 $0.00 $0.00
Disclosure

SEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · derivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,838

Underlying: Common Stock · 47,838 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 04, 2026.

F3 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 04, 2026.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 5,448 $22.23 $121,109.04
Disclosure

SEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,328

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 12,186 Not disclosed Not disclosed
Disclosure

SEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 1,271 shares acquired on February 28, 2025, under the Issuer's employee stock purchase plan.

Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:23 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 8,046 $26.70 $214,828.20
Disclosure

SEC source: 0001447362-25-000019 · wk-form4_1740432180.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,319

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 18, 2024

F2 · price: This transaction was executed in multiple trades at prices ranging from $26.47 to $27.10, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 6,169 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 9

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,170

Underlying: Common Stock · 6,169 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022.

F4 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022.

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 8

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs which vest in four equal installments beginning on December 10, 2021.

F3 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs which vest in four equal installments beginning on December 10, 2021.

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 2,773 $29.63 $82,163.99
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 6

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,365

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 6,169 Not disclosed Not disclosed
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 5

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 900 $29.63 $26,667.00
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 4

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,969

Read SEC document
December 10, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
December 09, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 14,617 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 7

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,233

Underlying: Common Stock · 14,617 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023.

F2 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023.

Read SEC document
December 09, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 6,571 $30.91 $203,109.61
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,869

Read SEC document
December 09, 2024 Filed Dec 11, 2024 21:51 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 14,617 Not disclosed Not disclosed
Disclosure

SEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:04 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 800 $30.40 $24,323.20
Disclosure

SEC source: 0001447362-24-000187 · wk-form4_1732050241.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,823

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 13, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $30.400 to $30.425, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:04 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 6,123 $29.87 $182,894.01
Disclosure

SEC source: 0001447362-24-000187 · wk-form4_1732050241.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,623

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 13, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $29.40 to $30.35, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 09, 2024 Filed Aug 13, 2024 22:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantPerformance-Based Stock Unit · Derivative 9,744 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · derivative · entry 3

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,744

Underlying: Common Stock · 9,744 shares

Expires not disclosed

F2 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date.

F2 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date.

F2 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date.

Read SEC document
August 09, 2024 Filed Aug 13, 2024 22:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 2,822 $26.83 $75,714.26
Disclosure

SEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,746

Read SEC document
August 09, 2024 Filed Aug 13, 2024 22:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantCommon Stock 9,745 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,568

F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on December 23, 2022 ("2022 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on August 9, 2024 (the "Initial Vesting Date").

Read SEC document
August 07, 2024 Filed Aug 13, 2024 22:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,400 $26.13 $141,091.20
Disclosure

SEC source: 0001447362-24-000129 · wk-form4_1723587221.xml · nonDerivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,823

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $25.845 to $26.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 07, 2024 Filed Aug 13, 2024 22:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 4,600 $25.20 $115,906.20
Disclosure

SEC source: 0001447362-24-000129 · wk-form4_1723587221.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,223

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $24.840 to $25.535, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: Includes 1,272 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan.

Read SEC document
June 10, 2024 Filed Jun 12, 2024 20:07 UTC EXAGEN INC. XGN · Entity 935 GrantStock Option(right to buy) · Derivative 9,000 $0.00 Strike: $1.99 $0.00
Disclosure

SEC source: 0001274737-24-000064 · wk-form4_1718222835.xml · derivative · entry 1

Stokes Frank · CIK 0001782815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2034-06-09

F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 23:00 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantRestricted Stock Units · Derivative 48,744 $0.00 $0.00
Disclosure

SEC source: 0001447362-24-000023 · wk-form4_1709766033.xml · derivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,744

Underlying: Common Stock · 48,744 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 04, 2025.

F2 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 04, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.